News and Press Releases
Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis
UK NHS grants HRA/REC approval for PEMP study with Peterborough and Cambridge hospitals Clinical observational study investigating underlying biology of endometriosis aims to uncover causal mechanisms and new druggable targets...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 19, 2026
NICE recommends UCB’s RYSTIGGO▼ (rozanolixizumab) for adults with antibody-positive generalised myasthenia gravis in Final Draft Guidance
Rozanolixizumab, discovered and developed in the UK, has been recommended by NICE as an add on treatment option for eligible adults with antibody-positive generalised myasthenia gravis (gMG) Recommendation represents three...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 29, 2026
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
21 May 2025 -- Surrey, UK -- Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab)...
Category: Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2025
NICE recommends Yselty▼ (linzagolix) for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis
1 May 2025 -- London, UK -- Theramex is pleased to announce that the National Institute for Health and Care Excellence (NICE) has recommended NHS reimbursement of the extended indication...
Category: Other, Pharmaceutical
Posted: May 1, 2025
Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS
Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands
NICE publishes guidance in England & Wales recommending Altuvoct (efanesoctocog alfa) as a treatment option for people with severe haemophilia A aged 2 years and over
2 April 2025 -- Stockholm, Sweden -- Sobi in the UK today announced that the National Institute for Health and Care Excellence (NICE) has issued its Final Guidance in England...
Category: Clinical Trials, Other, Pharmaceutical
Posted: April 2, 2025
Over a thousand people with multiple myeloma may be eligible for treatment with Nexpovio▼ (selinexor) following NICE recommendation addressing ‘significant unmet need’ for this incurable blood cancer
NEXPOVIO has been recommended for use in the NHS, offering the opportunity to improve patient outcomes in this challenging and complex cancer NEXPOVIO has the potential to address significant treatment...
Category: Biotechnology, Pharmaceutical
Posted: April 22, 2024
Veklury (remdesivir) recommended by NICE for treatment of COVID-19 in vulnerable adults and children
Remdesivir is the first antiviral treatment recommended by NICE to treat eligible children, including those with a high risk of serious illness from COVID-19 This decision secures long-term access to...
Category: Pharmaceutical
Posted: April 9, 2024
Jemperli (dostarlimab) becomes the first immunotherapy treatment to receive NICE recommendation for use, in line with its license, in eligible endometrial cancer patients in first line setting
This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or...
Category: Clinical Trials, Drug Discovery
Posted: March 5, 2024
NICE has issued guidance for GSK’s Omjjara (momelotinib) as a treatment option for disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
Myelofibrosis is a rare blood cancer that can result in the progressive scarring of bone marrow (fibrosis), impairing its normal function There are approximately 1,970 people living with myelofibrosis across...
Category: Clinical Trials
Posted: February 15, 2024
NICE Recommends Lilly’s Mirikizumab (OMVOH) for the Treatment of Eligible Adults with Moderately to Severely Active Ulcerative Colitis.
22 September 2023 -- Basingstoke, UK -- Eli Lilly and Company announced today that the National Institute for Health and Care Excellence (NICE) have recommended mirikizumab for the treatment of...
Category: Pharmaceutical
Posted: September 22, 2023
